Docetaxel in gastric cancer

European Journal of Cancer, Supplement

Volumn 2, Issue 7, 2004, Pages 52-58

  Van Cutsem, E ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Docetaxel; Gastric carcinoma; Interim analysis; Phase III

Indexed keywords

CISPLATIN; DOCETAXEL; FLUOROURACIL;

ADJUVANT CHEMOTHERAPY; ADULT; ADVANCED CANCER; AGED; ANALYTIC METHOD; ANOREXIA; CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG RESPONSE; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INFECTION; LETHARGY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; STATISTICAL SIGNIFICANCE; STOMACH CANCER; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; VOMITING;

EID: 2642544285     PISSN: 13596349     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcsup.2004.04.016     Document Type: Article

References (29)

1. Roth A.D., Ajani J. Docetaxel-based chemotherapy in the treatment of gastric cancer. Ann. Oncol. 14(Suppl 2):2003;ii41-ii44
2. Glimelius B., Ekstrom K., Hoffman K., et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann. Oncol. 8:1997;163-168
3. Waters J.S., Ross P.J., Popescu R.A., Cunningham D. New approaches to the treatment of gastro-intestinal cancer. Digestion. 58:1997;508-519
4. The Gastrointestinal Tumour Study Group. Randomised study of combination chemotherapy in unresectable gastric cancer. Cancer 1984, 53, 13-7
5. Vanhoefer U., Rougier P., Wilke H., et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J. Clin. Oncol. 18:2000;2648-2657
6. Cullinan S.A., Moertel C.G., Wieand H.S., et al. Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of gastric cancer. North Central Cancer Treatment Group. J. Clin. Oncol. 12:1994;412-416
7. Bamias A., Hill M.E., Cunningham D., et al. Epirubicin, cisplatin and protracted venous infusion of 5-fluorouracil for esophagogastric carcinoma: response, toxicity, quality of life and survival. Cancer. 77:1996;1978-1985
8. Webb A., Cunningham D., Scarffe J.H., et al. Randomised trial comparing epirubicin, cisplatin and fluorouracil versus fluorouracil, doxorubicin and methotrexate in advanced esophagogastric cancer. J. Clin. Oncol. 15:1997;261-267
9. Futatsuki K., Wakui A., Nakao I., et al. Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-11 Gastrointestinal Cancer Study Group. Gan To Kagaku Ryoho. 21:1994;1033-1038
10. Köhne C.H., Catane R., Klein B., et al. Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial. Brit. J. Cancer. 89:2003;997-1001
11. Di Cosimo S., Ferretti G., Fazio N., et al. Docetaxel in advanced gastric cancer - a review of the main clinical trials. Acta Oncol. 42:2003;693-700
12. Boku N., Ohtsu A., Shimada Y., et al. Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J. Clin. Oncol. 17:1999;319-323
13. Ajani J.A., Baker J., Pisters P.W., et al. CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study. Cancer. 94:2002;641-646
14. Ajani J.A., Baker J., Pisters P.W., et al. Irinotecan/cisplatin in advanced, treated gastric or gastroesophageal junction carcinoma. Oncology (Huntingt). 16(Suppl 5):2002;16-18
15. Blanke C.D., Haller D.G., Benson A.B., et al. A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with previously untreated gastric adenocarcinoma. Ann. Oncol. 12:2001;1575-1580
16. Findlay MPN, Ackland S, Gebski V, et al. Phase II study of irinotecan, leucovorin, and 5FU (ILF) in advanced gastric cancer. Proc Am Soc Clin Oncol 2001, 20 (Abstract 655)
17. Roth A.D., Maibach R., Fazio N., et al. 5-FU as protracted continuous infusion (5-FUpiv) can be added to full dose taxotere-cisplatin (TC) in advanced gastric carcinoma (AGC). Eur. J. Cancer. 35(Suppl 4):1999;S139
18. Ajani J.A. Docetaxel in combination for advanced gastric cancer. Gastric Cancer. 5(Suppl 1):2002;31-34
19. Bouche O, Raoul JL, Giovanini M, et al. Randomized phase II trial of LV5FU2, LV5FU2-cisplatinum or LV5FU2-irinotecan in patients (pts) with metastatic gastric or cardial adenocarcinoma (MGA): final results of study FFCD 9803. Proc Am Soc Clin Oncol 2003, 22 (Abstract 1033)
20. Dank M, Zaluski J, Barone C, et al. CPT-11 plus 5-fluorouracil (5-FU)/leucovorin (LV) versus cisplatin (CDDP) plus 5-FU: a randomized, multinational phase III study in first-line metastatic and locally recurrent gastric cancer (MGC). Proc Am Soc Clin Oncol 2003, 22 (Abstract 1000)
21. Ajani JA, Fodor M, Van Cutsem E, et al. Multinational randomised phase II trial of docetaxel and cisplatin with or without 5-fluorouracil in patients with advanced gastric or GE junction adenocarcinoma. Proc Am Soc Clin Oncol 2000, 19 (Abstact 247)
22. Van Cutsem E., Ajani J., Tjuladin S., et al. Docetaxel in combination with cisplatinum with or without 5-fluorouracil in patients with advanced gastric or GE junction adenocarcinoma. Preliminary results. Ann. Oncol. 11:2000;63. (A2760)
23. Ajani JA, Van Cutsem E, Moiseyenko V, et al. Docetaxel (D), cisplatin, 5 fluorouracil (F) for chemotherapy-naïve patients with metastatic or locally recurrent, unresectable gastric carcinoma (MCG): interim results of a randomised phase III trial. Proc Am Soc Clin Oncol 2003, 22 (Abstract 999)
24. Van Cutsem E, Moiseyenko V, Tjuladin S, et al. Docetaxel, cisplatin, 5-Fluorouracil compared to cisplatin and 5-fluouracil for chemotherapy- naïve patients with metastatic or locally recurrent, unresectable gastric carcinoma: interim results of a randomised phase III trial (V325). Eur J Cancer 2003, 5(1), abstact 20
25. Ohtsu A., Shimada Y., Shirao K., et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: the Japan Clinical Oncology Group Study (JCOG9205). J. Clin. Oncol. 21:2003;54-59
26. Icli F., Celik I., Aykan F., et al. A randomised phase III trial of etoposide, epirubicin, and cisplatin versus 5-fluorouracil, epirubicin and cisplatin in the treatment of patients with advanced gastric carcinoma: Turkish Oncology Group. Cancer. 83:1998;2475-2480
27. Waters J.S., Norman A., Cunningham D., et al. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Brit. J. Cancer. 80:1999;269-272
28. Kang Y, Kim T, Chang H, et al. A phase I/II trial of docetaxel, capecitabine, and cisplatin as first line chemotherapy for advanced gastric cancer. Proc Am Soc Clin Oncol 2003, 22 (Abstract 73)
29. Hawkins R, Cunningham D, Soerbye H, et al. Randomized phase II trial of docetaxel plus irinotecan versus docetaxel plus 5-fluorouracil (5FU) in patients with untreated advanced gastric adenocarcinoma (AGAC). Proc Am Soc Clin Oncol 2003, 22 (Abstract 1032)